Great Plains Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• ACCEL Lite: TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS
  In this interview, Drs. Steven E. Nissen and Anders Jeppsson discuss “TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS”.
• JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-US
  Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
• Secondary Cardiovascular Prevention For Survivors of Childhood Cancer
  Approximately half a million people in the United States are survivors of cancer diagnosed in childhood or adolescence. Over 50% of pediatric cancer patients have been treated with curative, but cardiotoxic, anthracycline-based therapies.
• ACC CardiaCast: Innovation in Action: Leveraging Wearables in Cardiovascular Care
  In this episode, ACC Chief Innovation Officer Dr. Ami Bhatt and Dr. Sanket Dhruva explore how wearables are shaping the future of personalized care.
• Research Suggests Long-Term Melatonin Use For Insomnia Increases HF Risk
  Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a large, multinational cohort study presented at AHA 2025.